First Horizon Advisors Inc. Lowers Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

First Horizon Advisors Inc. reduced its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,604 shares of the medical equipment provider’s stock after selling 103 shares during the period. First Horizon Advisors Inc.’s holdings in Intuitive Surgical were worth $3,447,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ISRG. Berbice Capital Management LLC purchased a new position in Intuitive Surgical during the fourth quarter valued at $26,000. MidAtlantic Capital Management Inc. bought a new position in shares of Intuitive Surgical during the 3rd quarter valued at about $33,000. Decker Retirement Planning Inc. purchased a new position in shares of Intuitive Surgical during the fourth quarter valued at about $36,000. Capital Performance Advisors LLP bought a new stake in shares of Intuitive Surgical in the third quarter worth about $38,000. Finally, Sierra Ocean LLC purchased a new stake in shares of Intuitive Surgical in the fourth quarter worth about $40,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 2.4 %

Shares of ISRG opened at $591.79 on Monday. The firm has a fifty day moving average price of $565.45 and a 200-day moving average price of $525.60. The firm has a market capitalization of $210.78 billion, a P/E ratio of 92.32, a P/E/G ratio of 5.85 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00.

Wall Street Analyst Weigh In

ISRG has been the subject of several research analyst reports. Leerink Partners lifted their price objective on Intuitive Surgical from $490.00 to $548.00 in a research note on Monday, January 27th. Royal Bank of Canada boosted their price target on shares of Intuitive Surgical from $611.00 to $641.00 in a research report on Monday, January 27th. BTIG Research increased their price objective on shares of Intuitive Surgical from $535.00 to $561.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Truist Financial boosted their target price on shares of Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Finally, Citigroup increased their price target on shares of Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $539.00, for a total transaction of $202,664.00. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,967,734. This trade represents a 6.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Jamie Samath sold 94 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $571.11, for a total value of $53,684.34. Following the completion of the sale, the chief financial officer now owns 2,630 shares of the company’s stock, valued at $1,502,019.30. This represents a 3.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,348 shares of company stock worth $3,587,582 in the last 90 days. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.